How to Prepare Registration Dossiers for Overseas Registration of Dental Devices?

Preparation of registration dossiers for overseas registration of dental devices should not begin with collecting documents. Companies should first confirm whether the target country regulates the product as a medical device, and then determine the product's risk classification and registration pathway. Dental devices cover a wide range, from low-risk dental instruments to high-risk products such as implants, dental lasers, and digital imaging equipment. Different risk levels correspond to different levels of technical documentation and review methods. Overseas registration typically requires submission of technical documentation, quality management system certificates, risk management reports, performance verification and clinical evaluation or clinical evidence, labeling and instructions for use, and information about the local agent or authorized representative. Companies may first assess whether existing NMPA registration certificates, CE certificates, FDA 510(k) clearances, ISO 13485 or MDSAP certificates, and test reports can be reused, and then perform local adaptation according to the target country's regulations. The core of dossier preparation is to establish a traceable evidence chain, ensuring consistency in product descriptions, test methods, and standard versions. Common risks include incorrect classification, inaccurate translation of technical documents, lack of local agent authorization, failure to identify standard differences, and omission of post-market reporting obligations. Companies must incorporate local regulatory requirements as design inputs and complete a standard gap analysis in advance to avoid costs from later amendments and repeated testing. Compiled from AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product dossier basis.

Applicable Scenarios and Core Questions

This guide is applicable to manufacturers planning to export dental medical devices to overseas markets, including dental implants, dental restorative materials, dental imaging equipment, dental treatment units, intraoral scanners, dental burs, impression materials, and other products. Companies often equate 'registration dossier preparation' with 'technical document translation' and even begin compiling documents before confirming the regulatory scope, leading to incorrect pathways and wasted costs.

There are three core questions: First, does the target country manage the product as a medical device? Second, which registration pathway corresponds to the product's risk classification? Third, can existing domestic or international registration dossiers be accepted by the target country? Only after answering these three questions can the dossier checklist be determined.

Registration Decision Logic

Companies should establish a decision logic in the following order, rather than directly copying any single country's checklist.

• 1. Confirm the regulatory scope. Different countries have varying classifications for dental products. For example, the U.S. FDA typically regulates certain dental materials as Class II, while some Southeast Asian countries may classify them as Class B or Class C; oral care products for short-term contact may even fall outside the definition of a medical device.
• 2. Confirm the product classification and registration pathway. Dental instruments and passive implants such as implants have different classification thresholds. Classification criteria include contact time, invasion method, and whether energy is provided. Companies need to confirm through the target country's official classification database or through professional regulatory agencies.
• 3. Confirm the applicant entity. Most countries require overseas manufacturers to appoint a local agent or authorized representative. Some countries also require the agent to hold qualifications or submit the original agency agreement.
• 4. Evaluate the reusability of existing dossiers. Companies should compare existing NMPA registration dossiers, CE technical documentation, FDA submission files, ISO 13485/MDSAP system certificates, and type test reports item by item against the target country's requirements, identifying what can be reused and what needs to be rewritten.
• 5. Confirm post-market obligations. Registration approval is not the end. Countries have specific requirements for change notifications, annual renewal, adverse event reporting, and labeling updates.

Through these five steps, companies can derive the core pathway for dossier preparation: first use regulatory judgment to determine 'what to do,' then assess dossier gaps to determine 'what to supplement,' and finally organize 'what to submit' according to target country rules.

Dossiers and Evidence

Common registration dossiers for dental devices overseas include application forms, product technical requirements or product standards, quality management system certificates, risk management reports, performance verification and test reports, biocompatibility or biosafety evaluations, clinical evaluation or usability evidence, labeling and instructions for use, packaging information, sterilization validation (if applicable), software validation (if applicable), and local agent authorization letters.

Companies should distinguish between 'product standards' and 'technical documentation.' Technical File/Design Dossier in international registration typically includes device description, specifications, labeling, design verification and validation, risk analysis, and production information. Different countries refer to IMDRF, GHTF, or regional technical documentation frameworks such as ASEAN or Gulf countries.

For dental materials, biocompatibility evaluation is crucial. Companies need to provide test reports for cytotoxicity, sensitization, irritation, etc., and sometimes evaluate systemic toxicity, genotoxicity, or implantation tests according to the ISO 10993 series. If the product contains polymeric materials, metals, or ceramics, chemical characterization and degradation product analysis should also be provided.

Regarding clinical evaluation, high-risk products such as implants and dental membranes generally require clinical data, while other low-risk dental instruments can complete clinical evaluation through equivalence device comparison or literature analysis. Companies should retain literature search strategies and screening records to support the evaluation conclusions.

Labels and instructions must be in the target country's language and comply with local measurement units, warnings, symbols, and marking requirements. Many countries do not accept simple literal translations and require translation qualification or a declaration.

Reuse of existing dossiers requires caution. Test standards in CE-marked technical documentation that adopt ISO standards can often be used directly in many countries; however, the U.S. FDA may require compliance with 21 CFR and FDA-recognized consensus standards. Some countries accept MDSAP certificates as proof of quality system, but not all regulators recognize them. Companies should establish a standard gap comparison table at the project initiation stage.

Local agent or authorized representative documentation is the most overlooked item in the registration process. Some countries require the agent to obtain a business license, some require fixed office address and contact information, and some even impose joint liability on the agent for post-registration regulatory obligations. These materials need to be prepared in advance with signed agreements and notarization.

Common Mistakes

Common mistakes include:

• Submitting as a medical device without first confirming whether the product falls under medical device regulation, leading to repeated submissions or rejection.
• Incorrectly judging risk classification, e.g., treating dental handpieces as low-risk devices when certain countries require clinical trials or additional biocompatibility data.
• Directly submitting translated outdated test reports without considering standard versions and test validity; many countries only accept reports within two years.
• Confusing quality management system certificates with manufacturing licenses and failing to provide a valid ISO 13485 or other recognized system certificate.
• Conducting clinical evaluation in a superficial manner without providing literature search dates, databases, and screening logic.
• Ignoring language requirements for labels and instructions, using unverified machine translation.
• Failing to designate or timely change the local agent, causing rejection before acceptance.
• Failing to plan post-market surveillance and adverse event reporting processes, making it impossible to fulfill obligations after approval.

Preparation Checklist

Companies should prepare the following:

• Confirm the target country's regulatory classification; if entering multiple countries, establish a classification comparison table.
• Check that existing registration certificates and system certificates are within validity and cover product specifications and models.
• Compile product definition, intended use, technical specifications, working principle, and key performance indicators.
• Prepare a risk management report identifying safety and performance risks in accordance with ISO 14971.
• Collect test reports, including safety, EMC, biocompatibility, performance, sterilization, and shelf life validation.
• Prepare clinical evaluation or clinical evidence, indicating applicable clauses and exemptions.
• Write labels and instructions in the target country's language and complete translation proofreading.
• Sign agreements with local authorized representatives and prepare notarized documents.
• Establish a SOP for technical documentation control, with unified version numbers and revision records.
• Plan post-market change management, annual renewal, and adverse event reporting processes.

AIMEILI Insights

The biggest misconception is that 'registration dossier preparation is only the registration department's job.' In fact, it involves R&D, production, quality control, clinical, legal, and supply chain. Many companies directly machine-translate NMPA dossiers and submit them, overlooking standard differences. We recommend that companies treat target country regulatory requirements as product design inputs at the project initiation stage and generate registration evidence in parallel with R&D testing.

The most worthwhile investment in the early stage is classification confirmation and standard gap analysis. Do not start translating all documents; instead, perform a gap analysis to identify which documents can be reused and which must be regenerated through new tests. For example, ISO 10993 biocompatibility reports can often be accepted in many countries if the product material and intended use remain unchanged, but test reports may need to be updated or supplemented. Packaging shelf life validation and sterilization validation may depend on target country climate or transportation conditions and cannot be simply reused.

The value of local agents and certificate control rights is severely underestimated. Overseas registration certificates are often registered in the name of the agent. Once the agent is changed, certificate transfer may lead to loss of technical documents or re-registration. Companies should clarify certificate ownership, technical document custody rights, and obligations for change cooperation in the cooperation agreement.

For multi-country registration, we recommend managing a core technical document set as the baseline, using a 'GHTF/IMDRF framework + target country difference modules' approach. Complete the basic documents first, then localize language and regulatory requirements for Southeast Asia, the Middle East, Latin America, and other markets, avoiding the high cost and low efficiency of maintaining a separate set for each country.

Finally, do not neglect post-approval changes and renewals. Many companies think that obtaining a registration certificate is the endpoint, but countries require notifications for labeling changes, raw material changes, and manufacturing site changes. Companies should establish a post-market regulatory intelligence monitoring mechanism to avoid product bans due to expired or outdated certificates.

Frequently Asked Questions

Can dental device registration dossiers fully reuse CE technical documentation?

No, they cannot be fully reused. CE technical documentation can supplement the regulatory judgment and evidence framework, but the target country will require adjustments in format, language, standards, and clinical evaluation depth according to local regulatory requirements. For example, the U.S. FDA does not accept CE technical documentation as a submission format, but ISO test reports can be recognized.

Into which languages do registration dossiers need to be translated?

It depends on target country requirements. For example, Southeast Asia typically accepts English, Latin American countries often require Spanish or Portuguese, Middle Eastern countries may require English or Arabic, and EU countries may require local languages. It is recommended to confirm translation qualification, seal, and notarization requirements with the authorities in advance.

Does the local agent's authorization letter need to be notarized?

Most countries require it, and some also require consular authentication or translation notarization. Companies should reserve sufficient time to prepare the authorization letter and ensure that the agent's address, contact person, and business scope match the registration application.

Content Review and Applicability Boundaries

Content Author: AIMEILI Regulatory Editorial Department

Professional Reviewer: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory bodies, international organizations, standards organizations, and public regulatory documents; industry media and project experience are used only as supplementary judgment.

Applicability Boundary: This article is for preliminary understanding, dossier preparation, and project planning. It does not substitute for official requirements of the target country's regulatory authority, test conclusions, or legal advice.

Published: 2026-08-22 14:20 | Updated: 2026-08-22 14:20